MiMedx Group is trading 6.4% down at $4.00 as investors digest a 35% revenue decline and the company's $350 million acquisition of Sanara MedTech.
- The stock is pulling back after a sharp run into and immediately after July 29 results, which highlighted significant Medicare-driven weakness in the wound care segment.
- Downward pressure is being compounded by a broader selloff across the healthcare sector as the market evaluates the integration of the Sanara deal.